Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORKA-002 in Moderate-to-Severe Plaque Psoriasis
NCT07474792Phase 2Active, not recruiting
- Sponsor
- Oruka Therapeutics
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ORKA-002 in plaque psoriasis, sponsored by Oruka Therapeutics. Started Mar 2026; status: active, not recruiting.
02
Drugs
ORKA-002
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07474792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474792.